Dillon Hill Capital LLC recently announced the acquisition of new stake in Applied DNA Sciences Inc. (NASDAQ:APDN). This fresh investment now brings its stake to 3.96% valued currently at $1.49 million. In addition, The Vanguard Group, Inc. raised its holdings by 7406.0 to 0.1 million shares. And BlackRock Fund Advisors has lifted its position by 0.00% or 1.0 shares – to 72512.0 shares.
With over 0.6 million Applied DNA Sciences Inc. (APDN) shares trading Wednesday and a closing price of $10.19 on the day, the dollar volume was approximately $6.16 million. The shares have shown a positive weekly performance of 35.24% and its price on 07/22/20 lost nearly -6.17%. Currently, there are 4.68M common shares owned by the public and among those 3.95M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for APDN have a consensus price objective of $21.50. The analysts have set the share’s price value over the next 12 months at a high of $22.00 and a low of $21.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Applied DNA Sciences Inc. stock is 2.00 for the next 12 months. But an upside of 53.68% will see the stock hit the forecast high price target while mean target price for the stock is $21.50.
Insiders at the company have transacted a total of 23 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 19 of these insider trades were purchases, accounting for 4,806,995 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 205,774 shares.
The top 3 mutual fund holders in Applied DNA Sciences Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 88084.0 shares of the company’s stock, all valued at over $0.71 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.44% of the shares outstanding.
Shares of Applied DNA Sciences Inc. (NASDAQ: APDN) opened at $10.90, up $0.04 from a prior closing price of $10.86. However, the script later closed the day at $10.19, down -6.17%. The company’s stock has a 5-day price change of 35.24% and 71.02% over the past three months. APDN shares are trading 159.19% year to date (YTD), with the 12-month market performance down to -4.27% lower. It has a 12-month low price of $2.52 and touched a high of $19.69 over the same period. Currently, 0.6 million shares have been traded, compared to an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.14%, 12.91%, and 64.55% respectively.
Institutional ownership of Applied DNA Sciences Inc. (NASDAQ: APDN) shares accounts for 14.30% of the company’s 4.68M shares outstanding. Mutual fund holders own 6.10%, while other institutional holders and individual stakeholders account for 8.57% and 3.54% respectively.
It has a market capitalization of $42.35M and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$4.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 21.38% over the week and 11.90% over the month.
Analysts forecast that Applied DNA Sciences Inc. (APDN) will achieve an EPS of -$0.67 for the current quarter, -$0.27 for the next quarter and -$0.81 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.73 while analysts give the company a high EPS estimate of -$0.62. Comparatively, EPS for the current quarter was -$1.6 a year ago. Earnings per share for the fiscal year are expected to increase by 38.90%, and 69.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Applied DNA Sciences Inc. (APDN) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the APDN, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 20, 2020, with the firm’s price target at $18-$22. H.C. Wainwright coverage for the Applied DNA Sciences Inc. (APDN) stock in a research note released on July 02, 2020 offered a Buy rating with a price target of $18. Maxim Group was of a view on November 14, 2016 that the stock is Buy, while Maxim Group gave the stock Buy rating on May 13, 2016, issuing a price target of $13- $9. Maxim Group on their part issued Buy rating on October 08, 2015.